<DOC>
	<DOCNO>NCT00004307</DOCNO>
	<brief_summary>RATIONALE : The urea cycle process nitrogen remove blood convert urea , waste product find urine . Urea cycle disorder inherit disorder cause lack enzyme remove ammonia bloodstream . Gene therapy treatment give change gene function normally . Studying treatment metabolism patient urea cycle disorder may helpful develop new treatment disorder . PURPOSE : Two-part clinical trial study treatment metabolism patient urea cycle disorder .</brief_summary>
	<brief_title>Study Treatment Metabolism Patients With Urea Cycle Disorders</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This protocol involve 2 clinical study . Part A metabolic study glutamine conversion urea different level protein intake , medication . Part B dose escalation study first-generation adenoviral vector E1 deletion E3 deletion substitution ( d1309 ) express ornithine transcarbamylase ( OTC ) . In Part A , diet control protein calorie . Intravenous glutamine urea administer . Controls give intravenous arginine , phenylacetate , benzoate . In Part B , group 3 patient give single low , intermediate , high dose intravenous OTC vector . Allopurinol administer every 12 hour 12 day . As 12/10/1999 , Part B study close .</detailed_description>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
	<mesh_term>Amino Acid Metabolism , Inborn Errors</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Part A . Patients least 6 month old ornithine transcarbamylase deficiency ( OTC ) , i.e . : Hemizygous OTC homozygous autosomal recessive disorder evidence complete enzyme deficiency Hemizygous OTC male late presentation presume evidence residual enzyme activity OTC heterozygotes ( molecular diagnosis ) severely symptomatic asymptomatic disease Obligate heterozygotes autosomal recessive disorder ( parent genotyped sibling ) Normal adult volunteer genotyped sibling enter control Part B. Metabolically stable heterozygous OTC female age 18 65 Orotic acid level least 5 time normal allopurinol Symptoms range severe asymptomatic acceptable No prior hospitalization hyperammonemia Exclusion criterion ( Parts A B ) : Acute chronic intercurrent illness Pregnancy Acute hyperammonemia</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>urea cycle disorder</keyword>
</DOC>